Rutkowski T, Białas B, Rembielak A, Fijałkowski M, Nowakowski K
I. Radiotherapy Clinic; Cancer Center Maria Sklodowska-Curie Memorial Institute, Gliwice, 44-101 Poland.
Neoplasma. 2002;49(3):197-200.
The retrospective analysis includes a group of 50 patients with primary, invasive vaginal cancer treated with brachytherapy in the period of 1982-1993. Over 80% cases were squamous cell carcinoma. There were 14 patients in stage I according to FIGO classification and 20%, 36%, and 16% of patients in stage II, III and IV, respectively. Twenty one patients (42%) received MDR brachytherapy using Cs137 source, the remaining 29 (58%) were treated with HDR using Co60 or Ir192 sources. Among 50 patients 31 (62%) received also external beam irradiation. An overall 5-year actuarial disease-free survival was 40%, and it was 78.6% (11/14), 40% (4/10), 27.8% (5/18), 0% (0/8) for stage I, II, III and IV, respectively. For MDR or HDR5-year disease-free survival was 38% and 41%, respectively. No influence of dose rate on survival has been found (p=0.7). Local failure occurred in 20 patients (40%). Recurrences appeared in 10 patients (20%). Late complications rate was 0% and 17% for MDR and HDR, respectively. Effectiveness of brachytherapy MDR and HDR was similar, whereas serious late complications developed more often after HDR brachytherapy.
回顾性分析纳入了1982年至1993年期间接受近距离放射治疗的50例原发性浸润性阴道癌患者。超过80%的病例为鳞状细胞癌。根据国际妇产科联盟（FIGO）分类，I期患者有14例，II期、III期和IV期患者分别占20%、36%和16%。21例患者（42%）使用Cs137源接受了中剂量率近距离放射治疗，其余29例（58%）使用Co60或Ir192源接受了高剂量率治疗。50例患者中有31例（62%）还接受了外照射。总体5年无病生存率为40%，I期、II期、III期和IV期的5年无病生存率分别为78.6%（11/14）、40%（4/10）、27.8%（5/18）、0%（0/8）。中剂量率或高剂量率的5年无病生存率分别为38%和41%。未发现剂量率对生存率有影响（p = 0.7）。20例患者（40%）出现局部失败。10例患者（20%）出现复发。中剂量率和高剂量率的晚期并发症发生率分别为0%和17%。中剂量率和高剂量率近距离放射治疗的疗效相似，而高剂量率近距离放射治疗后严重晚期并发症的发生更为常见。
